Woven Planet Holdings, a Subsidiary of Toyota, to Acquire CARMERA
15.7.2021 00:00:00 EEST | Business Wire | Press release
Woven Planet Holdings, Inc. (“Woven Planet”), a subsidiary of the Toyota Motor Corporation, announced the acquisition of CARMERA, Inc. (“CARMERA”), a U.S.-based spatial AI company, which specializes in bringing next-generation road intelligence to automated mobility at scale. This is the second major deal for Woven Planet in North America, following the April 2021 announcement to acquire Level 5, the self-driving division of Lyft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210714005892/en/
Proof of Concept in Tokyo (Still) (Graphic: Business Wire)
Once the deal is closed, the CARMERA team will report into the Automated Mapping Platform (“AMP”) organization of Woven Alpha, Inc. (“Woven Alpha”). Woven Alpha focuses on exploring new strategic areas for business expansion and incubates several innovative projects such as Woven City and Arene, which is Woven Planet’s open software platform. AMP is a connected crowdsourced software platform that supports the creation, development and distribution of high definition (“HD”) maps—a key enabler for smart and safe automated mobility.
The Woven Alpha team plans to develop AMP to become the most globally comprehensive road and lane network HD map platform, enabling high-precision localization support to automated vehicles. The acquisition of CARMERA will accelerate AMP’s shift from the R&D stage to the next phase of commercialization by bolstering the platform’s engineering team with top experts in the development of HD maps. In addition, it will provide access to CARMERA’s sophisticated map update, change management and IoT sensing technology.
Together, the teams will tap into CARMERA’s ability to successfully update HD maps from crowdsourced, camera-based inputs—a significantly cheaper and faster approach than traditional methods. This will strengthen AMP’s ability to serve a comprehensive set of road classes and features, reflecting changes in lane markings, traffic signals, signs and more in near real-time, and support its future multi-regional commercial launch.
CARMERA will join Woven Planet Group as a wholly-owned subsidiary, expanding the company’s footprint beyond its Tokyo headquarters by adding New York and Seattle offices to its planned offices in Silicon Valley and London.
Comment from Mandali Khalesi, Vice President of Automated Driving Strategy and Mapping, Woven Planet:
“AMP has been a key project of Woven Planet since its foundation, helping support its vision of ‘Mobility to Love, Safety to Live.’ We’ve been progressing steadily in bringing safe automated mobility to the passenger and commercial vehicle segments, such as our recent announcements with Isuzu Motors Limited and Hino Motors, Ltd., and with Mitsubishi Fuso Truck and Bus Corporation. I’m really excited to welcome CARMERA to Woven Planet. With CARMERA joining the team, we’ll be able to hit the accelerator. CARMERA’s software stack, which is focused on real-time HD map changes and proprietary hardware custom-tailored to crowdsourcing, is an ideal complement to AMP’s mapping efforts. In addition, their world-class experts will allow us to bring forward the execution of key strategic milestones and jumpstart operations in the United States.”
Comment from Ro Gupta, CEO and Co-founder, CARMERA:
“Woven Planet and AMP have been highly aligned with CARMERA’s culture and mission from the beginning. Our teams have a common view of the unmet need for ubiquity in advanced mobility data going forward, including maps. Woven Planet, thanks to its software-first automotive DNA, shares our commitment to the end-user—to creating a technology stack that can be used safely and without friction by all stakeholders from data originators through to data consumers. This validates and furthers our founding thesis that richer, faster spatial intelligence is both critical to the next generation of ‘Mobility for All’ and viable at global-production scale. I’m beyond excited for CARMERA to join the Woven Planet organization, as it continues to strengthen its footprint in North America and ramp up its software-first development of mobility innovations.”
An earlier partnership between Woven Planet—under its predecessor organization Toyota Research institute - Advanced Development, Inc.—and CARMERA in Tokyo, Detroit and Ann Arbor, Michigan, laid the groundwork for this deal. Woven Planet and CARMERA participated in collaborative projects in 2018, 2019 and 2020, which proved the companies can successfully develop and update HD maps from commodity, device-agnostic sources, such as commercially available dashboard-mounted cameras.
About Woven Planet Group
Woven Planet Group represents a carefully curated blend of expertise and resources dedicated to bringing the vision of “Mobility to Love, Safety to Live” to life. Through innovations and investments in automated driving, robotics, smart cities, and more, we are transforming how humankind lives, works, and moves. We exist to design, build, and deliver secure, connected, and sustainable mobility solutions that benefit all people worldwide. Founded in 2018 as Toyota Research Institute - Advanced Development (TRI-AD), Woven Planet Group is composed of four complementary companies: Woven Planet Holdings, Woven Core, Woven Alpha, and Woven Capital.
For more information, please visit: https://www.woven-planet.global/
About CARMERA
CARMERA is a spatial AI company, built on the revolution of vehicular crowdsourcing and remote sensing to capture street-level change, at global breadth and high definition depth. CARMERA employs an open systems approach to working with the world’s leading automotive companies, commercial mobility operators, and mapping platforms. With a team hailing from leading geospatial, machine learning and computer vision organizations, and venture backing from GV (Google Ventures) among others, the company is headquartered in New York City and Seattle. CARMERA is the recipient of multiple industry awards, including Frost & Sullivan’s 2020 North American Mapping Company of the Year.
For more information, please visit: https://www.carmera.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005892/en/
Contact information
Woven Planet Holdings, Inc.
pr@woven-planet.global
https://www.woven-planet.global/
CARMERA, Inc.
press@carmera.com
https://www.carmera.com/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
